In the United States, the incidence of people with asthma has nearly doubled over the past 20 years. It is possible for anyone to develop asthma, yet there are some people who are more predisposed to developing the disease, either due to genetic or environmental factors. Who is at risk for developing asthma and can steps be taken to reduce this risk?
In June 2003, Xolair, the first anti-IgE medication, received FDA approval, bringing hope and relief to adults and adolescents (12 years and over) with uncontrolled allergic asthma. Xolair has been touted as a breakthrough treatment for asthma, and rightly so. In two pivotal clinical trials, Xolair reduced asthma attacks by half and improved patients' asthma symptoms and ability to breathe (J Allergy Clin Immun 2001;108:184-190, and Eur Respir J 2001;18:254-261). Furthermore, study participants who took Xolair were able to decrease, and in some cases even eliminate, the daily required dose of inhaled corticosteroids.
Jeff and Mary Sutton of Omaha, Neb., spent months poring over the details of their February 2003 wedding and honeymoon. But something unexpected still disrupted their week-long trip to Orlando, Fla. Instead of soaking up the sun and racing between theme parks, the Suttons took an unscheduled ambulance ride to an emergency room.
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：